Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

57.1%

4 terminated/withdrawn out of 7 trials

Success Rate

42.9%

-43.6% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2

5(71.4%)

Phase 1

2(28.6%)

7Total

Phase 2(5)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02530307Phase 2Terminated

HT-3951 vs. Placebo in Stroke Rehabilitation

Role: lead

NCT03306329Phase 2Terminated

DNS-7801 vs. Placebo in Parkinson's Disease

Role: lead

NCT03254160Phase 2Terminated

DNS-3379 vs. Placebo in Stroke Rehabilitation

Role: lead

NCT02013310Phase 2Completed

HT-0712 vs. Placebo in Subjects With Age-Associated Memory Impairment (AAMI)

Role: lead

NCT01413932Phase 1Completed

Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder

Role: lead

NCT00758446Phase 2Completed

Efficacy and Safety Study of BLX-028914 in Subjects With Allergic Rhinitis

Role: lead

NCT01215552Phase 1Terminated

Study of the Inhibition of [11C]R-rolipram Binding to Brain Phosphodiesterase - 4 (PDE-4) by HT-0712

Role: lead

All 7 trials loaded